European Journal of Clinical Pharmacology

, Volume 63, Issue 1, pp 65–72

Impact of high dose statin trials on hospital prescribers

Pharmacoepidemiology and Prescription

Abstract

Background

The PROVE-IT and REVERSAL studies established that an intensive 80 mg/day dose of atorvastatin was superior to pravastatin 40 mg/day for the secondary prevention of coronary heart disease (CHD) following acute coronary syndromes and in limiting the progression of coronary atherosclerosis. We have evaluated the impact of the results from these studies on statin prescribing by hospital doctors in the 2 years following their publication.

Methods and results

Using a nationwide database, 18,894 patients receiving a total of 23,750 hospital discharge prescriptions for atorvastatin were identified between September 2002 and December 2005. From this cohort, patients newly commenced on, switched to, or dose titrated on atorvastatin by a hospital prescriber were identified. The mean daily atorvastatin dose on discharge was calculated for each month and the results were analysed using a segmented regression analysis. There was a significant and sustained increase in the mean atorvastatin dose used by hospital prescribers. This resulted in an increase of 12 mg, (95% CI 10.6, 13.4) in the mean dose prescribed by December 2005. This was attributable largely to a 16.4% (95% CI 13.5, 19.3), 17.2% (95% CI 14.0, 20.5) and 8.8% (95% CI 7.4, 10.2) increase in the prescribing of the 20 mg, 40 mg and 80 mg/day dosages, respectively.

Conclusion

The PROVE-IT and REVERSAL studies have had a significant impact on hospital prescribers’ choice of atorvastatin dose. It is likely that this has been the result of both the publication and effective promotion of results from these trials.

Keywords

Pharmacoepidemiology Statins Clinical trials 

References

  1. 1.
    Allery LA, Owen PA, Robling MR (1997) Why general practitioners and consultants change their clinical practice: a critical incident study. BMJ 314:870–874PubMedGoogle Scholar
  2. 2.
    Andrade SE, Walker AM, Gottlieb LK, Hollenberg NK, Testa MA, Saperia GM, Platt R (1995) Discontinuation of antihyperlipidemic drugs-do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 332:1125–1131PubMedCrossRefGoogle Scholar
  3. 3.
    Austin PC, Mamdani MM (2005) Impact of the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada. Circulation 112:1296–1300PubMedCrossRefGoogle Scholar
  4. 4.
    Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495–1504PubMedCrossRefGoogle Scholar
  5. 5.
    Cayley WE Jr (2006) High-dose statins and the IDEAL study. JAMA 295:2476–2479PubMedCrossRefGoogle Scholar
  6. 6.
    de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E (2004) Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292:1307–1316PubMedCrossRefGoogle Scholar
  7. 7.
    De BG, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongevillem J, Ebrahim S, Faergeman O, Graham I, Mancia G, Cats VM, Orth-Gomer K, Perk J, Pyorala K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D (2003) European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 10:S1–S10Google Scholar
  8. 8.
    DeMaria AN (2004) Prepublication embargo of news release. J Am Coll Cardiol 43:2359–2360PubMedCrossRefGoogle Scholar
  9. 9.
    Feely J, Chan R, McManus J, O’Shea B (1999) The influence of hospital-based prescribers on prescribing in general practice. Pharmacoeconomics 16:175–181PubMedCrossRefGoogle Scholar
  10. 10.
    Fontanarosa PB, Flanagin A (2000) Prepublication release of medical research. JAMA 284:2927–2929PubMedCrossRefGoogle Scholar
  11. 11.
    Gross CP, Steiner CA, Bass EB, Powe NR (2000) Relation between prepublication release of clinical trial results and the practice of carotid endarterectomy. JAMA 284:2886–2893PubMedCrossRefGoogle Scholar
  12. 12.
    Hersh AL, Stefanick ML, Stafford RS (2004) National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291:47–53PubMedCrossRefGoogle Scholar
  13. 13.
    Jones MI, Greenfield SM, Bradley CP (2001) Prescribing new drugs: qualitative study of influences on consultants and general practitioners. BMJ 323:378–381PubMedCrossRefGoogle Scholar
  14. 14.
    Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351:543–551PubMedCrossRefGoogle Scholar
  15. 15.
    Kassirer JP, Angell M (1997) Prepublication release of Journal articles. N Engl J Med 337:1762–1763PubMedCrossRefGoogle Scholar
  16. 16.
    Lamas GA, Pfeffer MA, Hamm P, Wertheimer J, Rouleau JL, Braunwald E (1992) Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators. N Engl J Med 327:241–247PubMedCrossRefGoogle Scholar
  17. 17.
    LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425–1435PubMedCrossRefGoogle Scholar
  18. 18.
    Majumdar SR, Almasi EA, Stafford RS (2004) Promotion and prescribing of hormone therapy after report of harm by the Women’s Health Initiative. JAMA 292:1983–1988PubMedCrossRefGoogle Scholar
  19. 19.
    Majumdar SR, McAlister FA, Soumerai SB (2003) Synergy between publication and promotion: comparing adoption of new evidence in Canada and the United States. Am J Med 115:467–472PubMedCrossRefGoogle Scholar
  20. 20.
    Miller LG, Liu H, Hays RD, Golin CE, Beck CK, Asch SM, Ma Y, Kaplan AH, Wenger NS (2002) How well do clinicians estimate patients’ adherence to combination antiretroviral therapy? J Gen Intern Med 17:1–11PubMedCrossRefGoogle Scholar
  21. 21.
    Murri R, Ammassari A, Trotta MP, De LA, Melzi S, Minardi C, Zaccarelli M, Rellecati P, Santopadre P, Soscia F, Scasso A, Tozzi V, Ciardi M, Orofino GC, Noto P, Monforte A, Antinori A, Wu AW (2004) Patient-reported and physician-estimated adherence to HAART: social and clinic center-related factors are associated with discordance. J Gen Intern Med 19:1104–1110PubMedCrossRefGoogle Scholar
  22. 22.
    Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN (2004) Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 1071–1080PubMedCrossRefGoogle Scholar
  23. 23.
    Ong HT, Cheah JS (2006) High-dose statins and the IDEAL study. JAMA 295:2476–2477PubMedCrossRefGoogle Scholar
  24. 24.
    Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J (2005) High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294:2437–2445PubMedCrossRefGoogle Scholar
  25. 25.
    Pryce AJ, Heatlie HF, Chapman SR (1996) Buccaling under the pressure: influence of secondary care establishments on the prescribing of glyceryl trinitrate buccal tablets in primary care. BMJ 313:1621–1624PubMedGoogle Scholar
  26. 26.
    Ravnskov U, Rosch PJ, Sutter MC (2006) High-dose statins and the IDEAL study. JAMA 295:2476–2479PubMedCrossRefGoogle Scholar
  27. 27.
    Ravnskov U, Rosch PJ, Sutter MC, Houston MC (2006) Should we lower cholesterol as much as possible? BMJ 332:1330–1332PubMedCrossRefGoogle Scholar
  28. 28.
    Shepherd J, Alcalde V, Befort PA, Boucher B, Erdmann E, Gutzwiller F, van Hemert TJ, Jordan-Ghizzo I, Menotti A, Schioldborg P, Thompson DR, Turner M, Umlauf B (1997) International comparison of awareness and attitudes towards coronary risk factor reduction: the HELP study. Heart European Leaders Panel. J Cardiovasc Risk 4:373–384PubMedCrossRefGoogle Scholar
  29. 29.
    Toma M, McAlister FA, Bialy L, Adams D, Vandermee B, Armstrong PW (2006) Transition from meeting abstract to full-length journal article for randomized controlled trials. JAMA 295:1281–1287PubMedCrossRefGoogle Scholar
  30. 30.
    Tu K, Mamdani MM, Jacka RM, Forde NJ, Rothwell DM, Tu JV (2003) The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. CMAJ 168:553–557PubMedGoogle Scholar
  31. 31.
    Usher C, Teeling M, Bennett K, Feely J (2006) Effect of clinical trial publicity on HRT prescribing in Ireland. Eur J Clin Pharmacol 62:307–310PubMedCrossRefGoogle Scholar
  32. 32.
    Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D (2002) Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 27:299–309PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Thomas I. Barron
    • 1
  • Kathleen Bennett
    • 1
  • John Feely
    • 1
  1. 1.Department of Pharmacology and Therapeutics, Trinity College DublinSt Jame’s HospitalDublin 8Ireland

Personalised recommendations